Urovant Sciences announced that the independent Data and Safety Monitoring Board has recommended the continuation of the phase 2a study of URO-902, a novel gene therapy product, in patients with overactive bladder and urge urinary incontinence. URO-902 has the potential to be the first gene therapy for patients with OAB. Following the recommendation of the DSMB, Urovant is proceeding with opening cohort 2 of the study with a dose of 48 mg or placebo. This randomized, double blind, placebo-controlled study will evaluate the efficacy, safety, and tolerability of a single administration of URO-902, a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy. URO-902 is administered via direct intradetrusor injections into the bladder wall under local anesthesia in patients who are experiencing OAB symptoms and UUI. The Phase 2a trial is expected to enroll approximately 80 female patients in two cohorts: the first cohort received either a single administration of 24 mg of URO-902 or matching placebo into the bladder wall, and the second cohort will receive 48 mg of URO-902 or matching placebo into the bladder wall. Patients will be followed for up to 48 weeks after initial administration. The primary outcome measure is the change in the average daily number of UUI episodes from baseline at week 12, as well as assessing the safety and tolerability of this new potential therapy. URO-902 has the potential to be the first gene therapy for patients with OAB. This innovative treatment has the potential to address an unmet need for patients who have failed oral pharmacologic therapies and are concerned with potential urinary retention or surgical interventions related to existing third-line OAB treatments.